Нейробутал is commonly used within the therapeutic domain of Central Hypersomnolence Disorders to manage severe, debilitating symptomatic patterns that interfere with daily functioning, which is relevant in conditions characterized by periods of heightened symptoms. The medication is primarily applied in treating core symptoms of Narcolepsy and Idiopathic Hypersomnia in adult patients.

The medication is applied in addressing symptom clusters that include chronic, overwhelming Excessive Daytime Sleepiness (EDS), episodic motor instability like Cataplexy, and profound nocturnal sleep fragmentation. By supporting management of nocturnal sleep symptoms, it may help ease the overall symptom burden, providing support that helps with maintaining functional stability and alertness.

“This therapeutic focus assists with maintaining functional stability and supports general well-being during symptomatic phases.”

Who can and cannot use Нейробутал?

Eligibility to use Нейробутал (Calcium oxybate) is strictly defined by official regulatory criteria, primarily based on age, existing medical conditions, and other concurrent therapies.

Populations Strictly Prohibited (Contraindications)

The medicine must not be used by patients with:

• Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency (an absolute contraindication).
• Concurrent use of sedative hypnotics or alcohol, as this is strictly prohibited.

Age and Condition-Based Restrictions

Interactions with other medicines and products

The official regulatory profile for Нейробутал (Calcium oxybate) is defined by its potential for central nervous system (CNS) depressant augmentation and specific pharmacokinetic effects.

Contraindicated Combinations

The co-administration of alcohol (ethanol) is formally contraindicated due to the documented risk of significant respiratory depression, hypotension, and profound sedation. The use of sedative hypnotics is also prohibited for co-administration due to the risk of additive CNS depressant effects, including syncope and death. The medication is further contraindicated in patients with Succinic Semialdehyde Dehydrogenase (SSADH) deficiency.

Pharmacokinetic and Pharmacodynamic Interactions

Concurrent use with other CNS depressants (e.g., opioid analgesics, benzodiazepines, sedating antidepressants, muscle relaxants) results in a pharmacodynamic interaction that may increase the risk of adverse CNS outcomes. Divalproex sodium causes a pharmacokinetic interaction that results in a mathbf25% mean increase in the systemic exposure ( AUC and C max) of oxybate. This interaction requires a mandatory adjustment of the oxybate dosage.

Timing and Population Constraints

The regulatory label specifies a timing-based rule that the medication must be administered at least 2 hours after a meal to prevent reduced absorption. Patients with hepatic impairment are a population where interaction management is noted, as the increased systemic exposure in this group necessitates a lower starting dosage when Divalproex sodium is co-administered.

Нейробутал, which is chemically gamma-hydroxybutyrate (GHB), targets the GABAB receptor as a full agonist, and it also interacts with a lower affinity GHB receptor as an agonist. In the central nervous system, this interaction results in the inhibition of neuronal firing via GABAergic pathways. The activation of the postsynaptic GABAB receptors by GHB initiates a G-protein-coupled inhibitory cascade. This involves the opening of G-protein-gated inwardly rectifying potassium (GIRK) channels, leading to a K^+ efflux and subsequent hyperpolarization of the neuronal membrane. Concurrently, the activation also leads to the inhibition of voltage-gated Ca^2+ channels, which reduces the influx of Ca^2+ and decreases the release of various excitatory neurotransmitters. The downstream molecular consequence of this dual action is a global attenuation of synaptic excitability and a corresponding reduction in central nervous system arousal, leading to systemic modulation of wakefulness and sleep architecture.

How to Use Нейробутал: Official Administration Guidelines

Нейробутал (Calcium oxybate) is intended for oral administration as part of a long-term maintenance protocol. The medicine must be prepared as a solution and administered according to a specific, time-dependent, divided-dosing schedule outlined in prescribing documentation.

Administration Protocol

The core use protocol requires the total nightly amount to be strictly divided into two equal doses. The first portion is taken orally at bedtime, and the second portion is scheduled for administration 2.5 to 4 hours later. Both doses must be prepared individually by diluting the prescribed amount in water (e.g., 60 milliliters) immediately before ingestion. It is a mandatory procedural constraint that these two portions are never mixed or combined for a single administration.

Dosing and Adjustment

Treatment typically begins with a low starting dose, such as 4.5 grams (g) per night, which is then gradually adjusted upward during a titration phase. Dose increases should not exceed 1.5 g per night and usually occur no more frequently than every one to two weeks, with the maximum recommended total dose not to exceed 9 g per night. The medicine must be consumed on an empty stomach, generally meaning at least two hours after eating, to ensure standard absorption kinetics.

Special Administration Instructions

For proper use, if the second dose is missed, it must be skipped entirely, and the patient should wait until the next scheduled night's administration. Furthermore, the protocol involves specific modifications for certain patient populations: individuals with hepatic impairment must begin treatment at a reduced dose, typically half the initial starting dose, such as 2.25 g per night. Upon treatment cessation, the official protocol mandates a required process of gradual dose reduction (tapering).

Research evidence / Overview of Studies for Нейробутал

Evidence for Use in Narcolepsy (Cataplexy and Excessive Daytime Sleepiness)

The research for Нейробутал (Gamma-oxybutyric Acid, Calcium Salt) in narcolepsy centers around controlled clinical trials. The core evidence examined two major symptoms: cataplexy attacks and Excessive Daytime Sleepiness (EDS). The main research design used for adults involved Phase 3 Randomized Controlled Trials (RCTs), where study participants were compared to a placebo over defined time intervals. Many of these trials utilized a randomized withdrawal period, where patients initially receiving the medicine were switched to a placebo to monitor symptom status.

Studies also explored various patient-reported outcomes describing perceived discomfort and functional imbalance, such as measures of nocturnal sleep disruption and overall Quality of Life (QoL). Research was conducted in both adults and pediatric patients starting at age 7 with narcolepsy. What remains uncertain are the long-term effects of the medicine. While short-term outcomes research is available, extended follow-up data is primarily derived from Open-Label Extension (OLE) studies, where a parallel placebo group was not included for comparison over the long term.

Evidence for Use in Idiopathic Hypersomnia (IH)

The research for the use of this medicine in Idiopathic Hypersomnia (IH) is also founded on Phase 3 Randomized Controlled Trials (RCTs). These studies were evaluated in adults with IH, using the randomized withdrawal design against a placebo. The research examined outcomes related to systemic or functional imbalance by measuring changes in scores on validated scales for Excessive Daytime Sleepiness (EDS) and the overall IH symptom severity scale.

Findings indicate that the studies reported comparisons between the active medicine period and the subsequent randomized withdrawal period for measured symptom outcomes. The data for certain groups remain insufficient, particularly for those with long sleep time in the context of IH, as these patients were represented in small numbers within the initial study cohorts. The long-term effects are not fully established, as continued follow-up is based largely on unblinded OLE studies.

What is Still Uncertain About the Research

Key gaps and uncertainties remain in the evidence base. Long-term effects, particularly relating to the low-sodium formulation's potential cardiovascular impact, are not fully established and require more research, as limited prospective data is currently available. The long-term safety and continuity of the observed patterns rely on data from unblinded studies.

Common questions about Нейробутал (FAQ)

Q: What are the official, recognized uses for Нейробутал?

The medication is officially indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy who are 7 years of age or older. It is also approved for treating idiopathic hypersomnia (IH) in adult patients.

Q: What is the official statement on Нейробутал's effectiveness?

Studies and official information indicate that the effectiveness of the medication has been established in controlled clinical trials. These trials supported its use for treating cataplexy and excessive daytime sleepiness associated with narcolepsy, as well as symptoms of idiopathic hypersomnia in adults.

Q: Is there a generic version of Нейробутал available?

Regulatory and availability information indicates that a generic version of this low-sodium mixed-salt formulation is currently not available in the United States.

Q: How quickly does Нейробутал start working after I take it?

Official product information advises that patients be in bed when the dose is taken, due to the risk of falling asleep abruptly. Clinical information indicates that sleep onset typically occurs within 5 to 15 minutes after taking a dose.

Q: Can Нейробутал affect my ability to drive or operate machinery?

Regulatory documents contain an explicit warning that the medication is a Central Nervous System (CNS) depressant and can impair judgment, thinking, or motor skills. Official warnings advise against driving or engaging in other hazardous activities for at least 6 hours after taking a dose.

Q: What if I start feeling unusual changes after beginning Нейробутал?

Official safety documents advise contacting a healthcare provider right away if a patient starts feeling new or worsening mental health problems, confusion, unusual or disturbing thoughts, or any other changes in behavior or mood.

Q: Can people with high blood pressure take Нейробутал?

Official prescribing information advises informing a healthcare provider about certain pre-existing conditions. These conditions include high blood pressure, heart failure, or kidney problems.

Q: Does Нейробутал require long-term use for noticeable effects?

Official product information indicates that treatment involves a gradual dose adjustment over several weeks. The maximum benefit is typically observed following this initial dose adjustment period. Clinical trials have also shown that certain adverse reactions were more common early in treatment and tended to decrease over time.

Q: How long does Нейробутал stay in the system after the last dose?

The active ingredient, oxybate, is known to have a short half-life in the body. This short half-life supports the requirement for the medication to be administered in two separate doses each night.

Q: How does the medicine’s classification relate to its uses?

Regulatory documents classify this medication as a Central Nervous System (CNS) depressant and a Schedule III controlled substance. This classification is the reason for specific safety warnings and for its restricted distribution through a specialized program.

Q: Why do patients often look for information on Нейробутал and weight gain?

In clinical trials, the medication was associated with changes in weight and appetite. Decreased weight or decreased appetite (anorexia) were reported as common side effects.

Q: Can Нейробутал be taken with common over-the-counter pain relievers?

Regulatory guidance advises patients to inform their healthcare provider about all medications they are taking, including both prescription and over-the-counter (OTC) products. This requirement covers common pain relievers, as disclosing all substances helps the provider determine the most appropriate treatment plan.

Q: Are there any known interactions between Нейробутал and caffeine?

Official regulatory guidance requires that patients report all substances they are using to their healthcare provider. This includes prescription and over-the-counter medicines, vitamins, minerals, and other supplements.

Q: Is it true that Нейробутал can interact with certain herbal products?

According to regulatory guidance, patients should inform their healthcare provider about all prescription and over-the-counter medicines, vitamins, minerals, and herbal products they are using. Disclosing these products helps ensure that the treatment plan safely accounts for all substances being taken.

Q: Does Нейробутал interact with birth control pills?

Official guidance requires patients to report all prescription and over-the-counter medicines they are taking, including birth control pills. Official guidance also advises informing the provider regarding pregnancy status or plans.

How to Store and Dispose of Нейробутал

Official regulatory documents mandate strict storage and disposal requirements for Нейробутал (Calcium oxybate) due to its classification as a controlled substance. The medicine must be stored at Controlled Room Temperature (20 C to 25 C) and protected from excessive heat and moisture.

Security and Stability

Storage must be in a safe, secure place such as a locked cabinet, and strictly out of the sight and reach of children and pets. The product must be kept in its original, tightly closed container. The original bottle's contents must be discarded 95 days after opening.

Disposal

The preferred method for disposal of unused or expired product is through an authorized drug take-back program. If a take-back program is unavailable, the liquid product must be poured down the sink drain and flushed with water. All personal information should be removed from the container label before disposal.